- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
May 9, 2024Property Insurance Claims Group 2024 Conference
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Generic Launches
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Summer 2014
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Taclonex |
Leo Pharma |
Calcipotriene / Betamethasone Dipropionate Ointment |
Sandoz |
Topical treatment of psoriasis vulgaris |
4/1/2014
|
Taclonex |
Leo Pharma |
Calcipotriene / Betamethasone Dipropionate Ointment |
Perrigo |
Topical treatment of psoriasis vulgaris |
4/1/2014
|
Ten-K |
Novartis |
Potassium Chloride Extended-release Capsules |
Par Pharm |
Hypokalemia with or without metabolic alkalosis, in digitalis intoxications, hypokalemic familial periodic paralysis |
4/7/2014
|
Lovaza |
GlaxoSmithKline |
Omega-3-Acid Ethyl Esters Capsules, USP |
Teva |
Adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia |
4/8/2014
|
Lunesta |
Sunovion Pharms |
Eszopiclone Tablets |
Dr. Reddy's Labs |
Insomnia |
4/15/2014
|
Lunesta |
Sunovion Pharms |
Eszopiclone Tablets |
Mylan |
Insomnia |
4/15/2014
|
Lunesta |
Sunovion Pharms |
Eszopiclone Tablets |
Teva |
Insomnia |
4/15/2014
|
Lunesta |
Sunovion Pharms |
Eszopiclone Tablets |
Glenmark Generics |
Insomnia |
4/15/2014
|
Ortho Evra |
Janssen Pharms |
Norelgestromin / Ethinyl Estradiol Transdermal System |
Mylan |
Prevention of pregnancy |
4/16/2014
|
Antara |
Lupin |
Fenofibrate Capsules |
Dr. Reddy's Labs |
Cholesterol |
4/23/2014
|
Differin |
Galderma Labs |
Adapalene gel |
Sandoz |
Topical treatment of acne vulgaris in patients 12 years of age and older |
4/28/2014
|
Catapres-TTS |
Boehringer Ingelheim |
Clonidine Transdermal System |
Actavis |
Hypertension |
5/7/2014
|
Astepro |
Media Pharms |
Azelastine hydrochloride nasal spray (0.15%) |
Perrigo / Impax Labs |
Nasal symptoms caused by seasonal allergies or environmental irritants |
5/12/2014
|
Exalgo |
Mallinckrodt |
Hydromorphone Hydrochloride Extended-release Tablets |
Actavis |
Moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time |
5/13/2014
|
Zyprexa Zydis |
Eli Lilly |
Olanzapine Orally Disintegrating Tablets |
Mylan |
Schizophrenia or the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder |
5/14/2014
|
Malarone |
GlaxoSmithKline |
Atovaquone / Proguanil Hydrochloride |
Mylan |
Prophylaxis of plasmodium falciparum malaria and the treatment of acute, uncomplicated P. falciparum malaria |
5/29/2014
|
Paraplatin |
Bristol-Myers Squibb |
Carboplatin Injection |
Mylan |
Advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents |
6/9/2014
|
Actonel |
Warner Chilcott |
Risedronate Sodium Tablets |
Mylan |
Osteoporosis in postmenopausal women |
6/11/2014
|
Cipro |
Bayer Healthcare |
Ciprofloxacin for Oral Suspension |
Lupin Pharms |
Infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations |
6/13/2014
|
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.